KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Current Assets (2016 - 2025)

Gilead Sciences (GILD) has disclosed Current Assets for 17 consecutive years, with $18.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 4.33% year-over-year to $18.3 billion, compared with a TTM value of $18.3 billion through Dec 2025, down 4.33%, and an annual FY2025 reading of $18.3 billion, down 4.33% over the prior year.
  • Current Assets was $18.3 billion for Q4 2025 at Gilead Sciences, up from $17.9 billion in the prior quarter.
  • Across five years, Current Assets topped out at $19.2 billion in Q4 2024 and bottomed at $12.3 billion in Q2 2024.
  • Average Current Assets over 5 years is $14.9 billion, with a median of $14.4 billion recorded in 2022.
  • The sharpest move saw Current Assets crashed 54.76% in 2021, then increased 20.94% in 2025.
  • Year by year, Current Assets stood at $14.8 billion in 2021, then dropped by 2.23% to $14.4 billion in 2022, then increased by 11.37% to $16.1 billion in 2023, then rose by 19.2% to $19.2 billion in 2024, then dropped by 4.33% to $18.3 billion in 2025.
  • Business Quant data shows Current Assets for GILD at $18.3 billion in Q4 2025, $17.9 billion in Q3 2025, and $14.7 billion in Q2 2025.